Efficacy of Dotarem® (Gd-DOTA) Versus Magnevist® (Gd-DTPA) for Late Gadolinium Enhancement Cardiac Magnetic Resonance and Relationship to Outcomes: A Pilot Study

Trial Profile

Efficacy of Dotarem® (Gd-DOTA) Versus Magnevist® (Gd-DTPA) for Late Gadolinium Enhancement Cardiac Magnetic Resonance and Relationship to Outcomes: A Pilot Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Gadopentetic acid (Primary) ; Gadoterate-meglumine (Primary)
  • Indications Coronary artery disease
  • Focus Diagnostic use
  • Most Recent Events

    • 22 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top